首页 > 最新文献

Research in Oncology最新文献

英文 中文
COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia: Report of Two Cases and Literature Review 慢性淋巴细胞白血病患者新冠肺炎感染2例报告及文献回顾
Pub Date : 2021-04-03 DOI: 10.21608/RESONCOL.2021.51731.1128
Noha Eisa, A. Alshehri, M. Assiri
Chronic lymphocytic leukemia (CLL) typically occurs in the elderly and has a highly variable clinical course. Infectious complications have been known to be a major cause of morbidity and mortality in CLL patients. The management of hematological malignancies, including CLL, during the COVID-19 pandemic is challenging. Here we describe two patients with CLL who got infected with SARS-COV-2 as confirmed by positive nasopharyngeal swab PCR. The 1st patient, who was receiving treatment for CLL-associated autoimmune hemolytic anemia, was hospitalized with mild COVID-19 symptoms. The 2nd patient, who was on active treatment for CLL, had asymptomatic COVID-19 infection and was not hospitalized. Both patients recovered from COVID-19 without related complications.
慢性淋巴细胞白血病(CLL)通常发生在老年人身上,临床病程变化很大。众所周知,感染性并发症是CLL患者发病率和死亡率的主要原因。在新冠肺炎大流行期间,包括CLL在内的血液系统恶性肿瘤的管理具有挑战性。在这里,我们描述了两名CLL患者,他们感染了严重急性呼吸系统综合征冠状病毒2型,经鼻咽拭子PCR阳性证实。第一名患者因CLL相关自身免疫性溶血性贫血接受治疗,因轻度新冠肺炎症状住院。第2名患者正在积极接受CLL治疗,患有无症状新冠肺炎感染,未住院。两名患者均从新冠肺炎中康复,无相关并发症。
{"title":"COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia: Report of Two Cases and Literature Review","authors":"Noha Eisa, A. Alshehri, M. Assiri","doi":"10.21608/RESONCOL.2021.51731.1128","DOIUrl":"https://doi.org/10.21608/RESONCOL.2021.51731.1128","url":null,"abstract":"Chronic lymphocytic leukemia (CLL) typically occurs in the elderly and has a highly variable clinical course. Infectious complications have been known to be a major cause of morbidity and mortality in CLL patients. The management of hematological malignancies, including CLL, during the COVID-19 pandemic is challenging. Here we describe two patients with CLL who got infected with SARS-COV-2 as confirmed by positive nasopharyngeal swab PCR. The 1st patient, who was receiving treatment for CLL-associated autoimmune hemolytic anemia, was hospitalized with mild COVID-19 symptoms. The 2nd patient, who was on active treatment for CLL, had asymptomatic COVID-19 infection and was not hospitalized. Both patients recovered from COVID-19 without related complications.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47499961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dosimetric Comparison of Pelvic Bone Marrow Preservation between Volumetric-Modulated Arc Therapy and Intensity-Modulated Radiotherapy in Radical Radiotherapy of High-Risk Prostate Cancer 在高危前列腺癌根治性放疗中,体积调节电弧治疗与调强放疗对盆腔骨髓保存的剂量学比较
Pub Date : 2019-12-01 DOI: 10.21608/RESONCOL.2019.12451.1077
E. Saad, K. Elshahat, Hussein M. Metwally
Background: Pelvic bone marrow (PBM) preservation is one of the factors that should be taken into consideration while choosing a technique for radiotherapy of pelvic malignancies. Aim: To dosimetrically compare between volumetric-modulated arc therapy (VMAT) and intensity-modulated radiotherapy (IMRT) in PBM preservation in radical treatment of high-risk prostate cancer. Methods: In 26 patients with high-risk prostatic carcinoma, dual arc VMAT and 7 fields IMRT plans were generated. In every patient, two targets were defined, clinical target volume (CTV) including the prostate and seminal vesicles (CTV-PSV) and CTV including pelvic lymph nodes (CTV-LN). The organs at risk delineated were the rectum, urinary bladder, small intestine, bulb of the penis, femoral heads bilaterally and PBM. The dose prescribed to the CTV-PSV was 76 Gy in 38 fractions given over 7.5 weeks and the dose to CTV-LN was 54 Gy in 38 fractions given over 7.5 weeks. Planning target volume (PTV) was created from the CTV with a margin of 5 mm in all direction. For assessment of PBM dose, V10, V20, V30, V40, V50 and mean dose were calculated. The dose volume histogram of PTV and PBM for both techniques was compared. Results: The mean dose of PTV 54 Gy was achieved in both techniques adequately with better sparing of organs at risk with the VAMT technique. The mean dose for PBM in the VMAT technique was significantly less than that in the IMRT (21.7 Gy vs. 25.8 Gy, respectively; p < 0.001). The significant differences in PBM doses were in the range of 20 Gy to 40 Gy. Conclusion: In radical treatment of prostate cancer, VMAT technique can offer comparable conformality to IMRT with better PBM preservation. Awareness of PBM delineation and reduction of its doses using VMAT can help to decrease the hematological toxicity.
背景:盆腔骨髓(PBM)的保存是选择盆腔恶性肿瘤放射治疗技术时应考虑的因素之一。目的:比较容量调制电弧治疗(VMAT)和强度调制放射治疗(IMRT)在高危前列腺癌根治性治疗中PBM保存的剂量。方法:在26例高危前列腺癌患者中,生成双弧VMAT和7场IMRT计划。在每个患者中,定义了两个靶点,包括前列腺和精囊的临床靶体积(CTV)和包括盆腔淋巴结的CTV(CTV-LN)。危险器官包括直肠、膀胱、小肠、阴茎球、双侧股骨头和PBM。对CTV-PSV的处方剂量为76Gy,在7.5周内给药的38个组分中,对CTV-LN的剂量为54Gy。计划目标体积(PTV)由CTV创建,在所有方向上具有5mm的裕度。为了评估PBM剂量,计算V10、V20、V30、V40、V50和平均剂量。比较两种技术的PTV和PBM的剂量体积直方图。结果:两种技术均能充分达到PTV 54Gy的平均剂量,VAMT技术能更好地保留危险器官。VMAT技术中PBM的平均剂量显著低于IMRT(分别为21.7 Gy和25.8 Gy;p<0.001)。PBM剂量的显著差异在20 Gy至40 Gy之间。了解PBM的描述并使用VMAT减少其剂量有助于降低血液学毒性。
{"title":"Dosimetric Comparison of Pelvic Bone Marrow Preservation between Volumetric-Modulated Arc Therapy and Intensity-Modulated Radiotherapy in Radical Radiotherapy of High-Risk Prostate Cancer","authors":"E. Saad, K. Elshahat, Hussein M. Metwally","doi":"10.21608/RESONCOL.2019.12451.1077","DOIUrl":"https://doi.org/10.21608/RESONCOL.2019.12451.1077","url":null,"abstract":"Background: Pelvic bone marrow (PBM) preservation is one of the factors that should be taken into consideration while choosing a technique for radiotherapy of pelvic malignancies. \u0000Aim: To dosimetrically compare between volumetric-modulated arc therapy (VMAT) and intensity-modulated radiotherapy (IMRT) in PBM preservation in radical treatment of high-risk prostate cancer. \u0000Methods: In 26 patients with high-risk prostatic carcinoma, dual arc VMAT and 7 fields IMRT plans were generated. In every patient, two targets were defined, clinical target volume (CTV) including the prostate and seminal vesicles (CTV-PSV) and CTV including pelvic lymph nodes (CTV-LN). The organs at risk delineated were the rectum, urinary bladder, small intestine, bulb of the penis, femoral heads bilaterally and PBM. The dose prescribed to the CTV-PSV was 76 Gy in 38 fractions given over 7.5 weeks and the dose to CTV-LN was 54 Gy in 38 fractions given over 7.5 weeks. Planning target volume (PTV) was created from the CTV with a margin of 5 mm in all direction. For assessment of PBM dose, V10, V20, V30, V40, V50 and mean dose were calculated. The dose volume histogram of PTV and PBM for both techniques was compared. \u0000Results: The mean dose of PTV 54 Gy was achieved in both techniques adequately with better sparing of organs at risk with the VAMT technique. The mean dose for PBM in the VMAT technique was significantly less than that in the IMRT (21.7 Gy vs. 25.8 Gy, respectively; p < 0.001). The significant differences in PBM doses were in the range of 20 Gy to 40 Gy. \u0000Conclusion: In radical treatment of prostate cancer, VMAT technique can offer comparable conformality to IMRT with better PBM preservation. Awareness of PBM delineation and reduction of its doses using VMAT can help to decrease the hematological toxicity.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45006294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Randomized Prospective Study Comparing Conventional Versus Hypofractionated Adjuvant Radiotherapy in Node-Positive Breast Cancer 比较传统与低分割辅助放疗治疗淋巴结阳性乳腺癌的随机前瞻性研究
Pub Date : 2019-12-01 DOI: 10.21608/RESONCOL.2019.12516.1078
Mai Atef, E. Sheikh, M. Ellithy, K. Naguib, Amr Shafik Tawfik
Background: Hypofractionated radiotherapy in early breast cancer yields equivalent or better outcome in terms of efficacy, toxicity, cosmesis and cost-effectiveness. However, its role in node-positive breast cancer is less clear. Aim: To compare between adjuvant conventional and hypofractionated radiotherapy in node-positive breast cancer. Methods: Prospective pilot study of 66 node-positive breast cancer patients recruited over 1 year in a single institution. Patients were randomized to receive adjuvant conventional radiotherapy 200 cGy x 25 fractions with 200 cGy x 5 fractions boost to the tumor bed in case of breast conservation (control arm) or hypofractionated radiotherapy 266 cGy x 16 fractions with 266 cGy x 4 fractions boost to the tumor bed in case of breast conservation (intervention arm). The end points were disease-free survival, cosmetic outcome, ipsilateral arm lymphedema and acute skin reactions. Results: Disease-free survival did not differ significantly between the two treatment arms (p = 0.6) and the 2-year disease-free survival rate was 87% and 89% in the hypofractionated and conventional arms. The rate of excellent/good cosmetic score was higher in the hypofractionated arm than the conventional as rated by patients (71% vs. 46%, p = 0.182) and physicians (29% vs. 8%, p = 0.32). Hypofractionation, when compared to conventional fractionation, was associated with less arm lymphedema (22% vs. 40%, p = 0.149), dry desquamation (28% vs. 53%, p = 0.04), skin darkness (0% vs. 15%, p = 0.054) and wet desquamation (16% vs. 21%, p = 0.601). Conclusion: Hypofractionated adjuvant radiotherapy in node-positive breast cancer patients is equivalent to conventional fractionation as regards disease-free survival, cosmetic outcome and arm lymphedema with less early skin reactions.
背景:低分割放疗在早期乳腺癌的疗效、毒性、美观性和成本效益方面具有同等或更好的结果。然而,它在淋巴结阳性乳腺癌中的作用尚不清楚。目的:比较常规辅助放疗与低分割放疗对淋巴结阳性乳腺癌的治疗效果。方法:前瞻性试点研究,66名淋巴结阳性乳腺癌患者在一个机构招募超过1年。患者随机接受常规辅助放疗,保乳组200 cGy × 25分次,200 cGy × 5分次强化至肿瘤床(对照组);保乳组266 cGy × 16分次,266 cGy × 4分次强化至肿瘤床(干预组)。终点为无病生存期、美容效果、同侧手臂淋巴水肿和急性皮肤反应。结果:两组无病生存率无显著差异(p = 0.6),低分割组和常规组的2年无病生存率分别为87%和89%。患者(71% vs. 46%, p = 0.182)和医生(29% vs. 8%, p = 0.32)对低分割组美容评分优良率均高于常规组。与常规分离术相比,低分离术与手臂淋巴水肿减少(22%对40%,p = 0.149)、干脱屑(28%对53%,p = 0.04)、皮肤暗沉(0%对15%,p = 0.054)和湿脱屑(16%对21%,p = 0.601)相关。结论:低分割辅助放疗在淋巴结阳性乳腺癌患者的无病生存率、美容效果和上臂淋巴水肿方面与常规分割相当,且早期皮肤反应较少。
{"title":"Randomized Prospective Study Comparing Conventional Versus Hypofractionated Adjuvant Radiotherapy in Node-Positive Breast Cancer","authors":"Mai Atef, E. Sheikh, M. Ellithy, K. Naguib, Amr Shafik Tawfik","doi":"10.21608/RESONCOL.2019.12516.1078","DOIUrl":"https://doi.org/10.21608/RESONCOL.2019.12516.1078","url":null,"abstract":"Background: Hypofractionated radiotherapy in early breast cancer yields equivalent or better outcome in terms of efficacy, toxicity, cosmesis and cost-effectiveness. However, its role in node-positive breast cancer is less clear. \u0000Aim: To compare between adjuvant conventional and hypofractionated radiotherapy in node-positive breast cancer. \u0000Methods: Prospective pilot study of 66 node-positive breast cancer patients recruited over 1 year in a single institution. Patients were randomized to receive adjuvant conventional radiotherapy 200 cGy x 25 fractions with 200 cGy x 5 fractions boost to the tumor bed in case of breast conservation (control arm) or hypofractionated radiotherapy 266 cGy x 16 fractions with 266 cGy x 4 fractions boost to the tumor bed in case of breast conservation (intervention arm). The end points were disease-free survival, cosmetic outcome, ipsilateral arm lymphedema and acute skin reactions. \u0000Results: Disease-free survival did not differ significantly between the two treatment arms (p = 0.6) and the 2-year disease-free survival rate was 87% and 89% in the hypofractionated and conventional arms. The rate of excellent/good cosmetic score was higher in the hypofractionated arm than the conventional as rated by patients (71% vs. 46%, p = 0.182) and physicians (29% vs. 8%, p = 0.32). Hypofractionation, when compared to conventional fractionation, was associated with less arm lymphedema (22% vs. 40%, p = 0.149), dry desquamation (28% vs. 53%, p = 0.04), skin darkness (0% vs. 15%, p = 0.054) and wet desquamation (16% vs. 21%, p = 0.601). \u0000Conclusion: Hypofractionated adjuvant radiotherapy in node-positive breast cancer patients is equivalent to conventional fractionation as regards disease-free survival, cosmetic outcome and arm lymphedema with less early skin reactions.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43605464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicopathological Characteristics and Survival of Triple-Negative Breast Cancer Patients: A single Institution Study from Egypt 癌症三阴性患者的临床病理特征和生存率:埃及的一项单一机构研究
Pub Date : 2019-06-01 DOI: 10.21608/RESONCOL.2019.11625.1076
W. Makar
Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is characterized by being more aggressive, presentation in younger age, and higher response rate to chemotherapy. It is more likely to recur and to metastasize early. Methods: Retrospective review of the medical records of TNBC patients treated in a single Egyptian cancer center during a 4-year period. Results: Sixty-five patients were included. Forty-six percent of patients were < 50 years old and 22% had a positive family history. Ten (15%) patients were metastatic at presentation. Modified radical mastectomy was performed in 42% of patients and adjuvant chemotherapy was administered in 55% of them. Relapse occurred in 12 (22%) out of 55 patients who had no distant metastasis at presentation (M0). The overall survival rate of M0 patients at 12, 24 and 36 months was 96%, 91% and 88%; respectively. The disease-free survival rate of M0 patients at 12, 24 and 36 months was 90%, 81% and 71%; respectively. Conclusion: In Egyptian female patients,TNBC is an aggressive subtype of breast cancer that occurs at younger age. Frequently, it is of high grade and presents in an advanced stage.
背景:三阴性乳腺癌(TNBC)是乳腺癌的一种亚型,其特点是更具侵袭性,出现在较年轻的年龄,对化疗的反应率较高。它更容易复发和早期转移。方法:回顾性分析4年间在埃及某癌症中心接受治疗的TNBC患者的医疗记录。结果:纳入65例患者。46%的患者年龄小于50岁,22%的患者有阳性家族史。10例(15%)患者出现转移。42%的患者行改良根治性乳房切除术,55%的患者行辅助化疗。55例患者在就诊时无远处转移(M0),其中12例(22%)复发。M0患者12、24、36个月总生存率分别为96%、91%、88%;分别。M0患者12、24、36个月无病生存率分别为90%、81%、71%;分别。结论:在埃及女性患者中,TNBC是一种侵袭性亚型乳腺癌,发生在较年轻的年龄。通常,它是高品位的,呈现在高级阶段。
{"title":"Clinicopathological Characteristics and Survival of Triple-Negative Breast Cancer Patients: A single Institution Study from Egypt","authors":"W. Makar","doi":"10.21608/RESONCOL.2019.11625.1076","DOIUrl":"https://doi.org/10.21608/RESONCOL.2019.11625.1076","url":null,"abstract":"Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is characterized by being more aggressive, presentation in younger age, and higher response rate to chemotherapy. It is more likely to recur and to metastasize early. Methods: Retrospective review of the medical records of TNBC patients treated in a single Egyptian cancer center during a 4-year period. Results: Sixty-five patients were included. Forty-six percent of patients were < 50 years old and 22% had a positive family history. Ten (15%) patients were metastatic at presentation. Modified radical mastectomy was performed in 42% of patients and adjuvant chemotherapy was administered in 55% of them. Relapse occurred in 12 (22%) out of 55 patients who had no distant metastasis at presentation (M0). The overall survival rate of M0 patients at 12, 24 and 36 months was 96%, 91% and 88%; respectively. The disease-free survival rate of M0 patients at 12, 24 and 36 months was 90%, 81% and 71%; respectively. Conclusion: In Egyptian female patients,TNBC is an aggressive subtype of breast cancer that occurs at younger age. Frequently, it is of high grade and presents in an advanced stage.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41654574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcome of Treatment of Giant-Cell Tumor of Bone: a Single-Institutional Retrospective Study 骨巨细胞瘤治疗效果的单一机构回顾性研究
Pub Date : 2019-06-01 DOI: 10.21608/RESONCOL.2019.7254.1072
M. Elshenawy, A. Badran, A. Elshentenawy, A. Eldali, M. Memon
Background: Giant-cell tumor of bone (GCTB) is a locally aggressive tumor which metastasizes infrequently to the lungs. The standard treatment of GCTB was surgery until the approval of denosumab. Aim: To describe the outcome of treatment of this rare tumor and to determine factors that influence survival.  Methods: Retrospective review of the medical records of GCTB patients treated at our institution. Collected data includes: clinicopathological data, treatment modalities and possible prognostic factors. Results: Forty-two patients were identified between May 2008 and November 2017. Their median age was 31 years, and the majority (62%) were females. The commonest primary sites were the upper and lower limbs (50% and 43%, respectively). Eight (19%) patients initially presented with lung metastases. Thirteen (31%) patients received denosumab as first line treatment before surgery and 12 of them underwent surgery post-denosumab. Denosumab was given after recurrence in 12 (29%) patients [8 (19%) with lung metastasis and 4 (10%) with localized disease]. The objective response rate to denosumab after recurrence was 50%. Four (10%) patients achieved complete response and 2 (5%) partial response. After a median follow up of 4.7 years, 6 (14%) patients had local recurrence and 8 (19%) had lung metastasis with no recorded deaths. The 5-year progression-free survival rate was 61%. Conclusion: Denosumab is effective and tolerable in the management of GCTB preoperatively in localized disease to facilitate surgery and in the management of metastatic disease. Multi-institutional prospective studies are needed for further assessment.
背景:骨巨细胞瘤(GCTB)是一种局部侵袭性肿瘤,很少转移到肺部。GCTB的标准治疗方法是手术治疗,直到德诺舒单抗获得批准。目的:描述这种罕见肿瘤的治疗结果,并确定影响生存率的因素。方法:回顾性分析我院治疗的GCTB患者的病历资料。收集的数据包括:临床病理数据、治疗方式和可能的预后因素。结果:在2008年5月至2017年11月期间,共确认了42名患者。她们的中位年龄为31岁,大多数(62%)是女性。最常见的原发部位是上肢和下肢(分别为50%和43%)。8名(19%)患者最初表现为肺转移。13名(31%)患者在手术前接受了狄诺沙单抗的一线治疗,其中12名患者在狄诺沙丸后接受了手术。12名(29%)患者复发后服用Denosumab[8名(19%)肺转移患者和4名(10%)局限性疾病患者]。复发后对狄诺沙单抗的客观有效率为50%。4名(10%)患者获得完全缓解,2名(5%)患者获得部分缓解。中位随访4.7年后,6名(14%)患者出现局部复发,8名(19%)患者出现肺转移,无死亡记录。5年无进展生存率为61%。结论:Denosumab在局限性疾病术前治疗GCTB是有效且可耐受的,有助于手术和转移性疾病的治疗。需要多机构前瞻性研究进行进一步评估。
{"title":"Outcome of Treatment of Giant-Cell Tumor of Bone: a Single-Institutional Retrospective Study","authors":"M. Elshenawy, A. Badran, A. Elshentenawy, A. Eldali, M. Memon","doi":"10.21608/RESONCOL.2019.7254.1072","DOIUrl":"https://doi.org/10.21608/RESONCOL.2019.7254.1072","url":null,"abstract":"Background: Giant-cell tumor of bone (GCTB) is a locally aggressive tumor which metastasizes infrequently to the lungs. The standard treatment of GCTB was surgery until the approval of denosumab. Aim: To describe the outcome of treatment of this rare tumor and to determine factors that influence survival.  Methods: Retrospective review of the medical records of GCTB patients treated at our institution. Collected data includes: clinicopathological data, treatment modalities and possible prognostic factors. Results: Forty-two patients were identified between May 2008 and November 2017. Their median age was 31 years, and the majority (62%) were females. The commonest primary sites were the upper and lower limbs (50% and 43%, respectively). Eight (19%) patients initially presented with lung metastases. Thirteen (31%) patients received denosumab as first line treatment before surgery and 12 of them underwent surgery post-denosumab. Denosumab was given after recurrence in 12 (29%) patients [8 (19%) with lung metastasis and 4 (10%) with localized disease]. The objective response rate to denosumab after recurrence was 50%. Four (10%) patients achieved complete response and 2 (5%) partial response. After a median follow up of 4.7 years, 6 (14%) patients had local recurrence and 8 (19%) had lung metastasis with no recorded deaths. The 5-year progression-free survival rate was 61%. Conclusion: Denosumab is effective and tolerable in the management of GCTB preoperatively in localized disease to facilitate surgery and in the management of metastatic disease. Multi-institutional prospective studies are needed for further assessment.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41986466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pharmacokinetic-Based Chemotherapy Dosing in Advanced Head and Neck Cancer: A Mini Review 晚期癌症癌药物动力学化疗剂量的初步研究
Pub Date : 2019-06-01 DOI: 10.21608/RESONCOL.2019.10154.1074
Abdelhamid M. Fouad, A. Gabal, Mariam Elhaddad
Despite the continuous evolution in different treatment modalities for head and neck cancer (HNC), severe side effects of medications remain a challenge. Chemotherapy (CTH)-induced toxicities may lead to alterations in the treatment plan in the form of dose reduction, treatment delay or even discontinuation of treatment. Many efforts were done to overcome the impact of CTH-induced toxicity on HNC treatment. One of the explored strategies is the pharmacokinetic (PK)-based dosing of CTH. A literature search for trials investigating PK-based CTH dosing in HNC from 1988 to 2018 was performed. Few clinical studies including one randomized clinical trial were identified. The limited evidence obtained from these studies shows that PK-based CTH dosing in HNC results in significantly less toxicities with no detrimental impact on treatment outcome. The current evidence is not enough to recommend the routine use of PK-based CTH dosing in HNC. However, the promising results call for future studies.
尽管头颈癌(HNC)的不同治疗方式不断发展,但药物的严重副作用仍然是一个挑战。化疗(CTH)诱导的毒性可能导致治疗计划的改变,其形式为剂量减少、治疗延迟甚至停止治疗。为了克服cth诱导的毒性对HNC治疗的影响,人们做了许多努力。其中一个探索的策略是基于药代动力学(PK)给药CTH。对1988年至2018年HNC中基于哌啶酮的CTH给药试验进行文献检索。很少有临床研究,包括一项随机临床试验。从这些研究中获得的有限证据表明,在HNC中使用基于磷酸基的CTH剂量可显著降低毒性,对治疗结果没有不利影响。目前的证据不足以推荐在HNC中常规使用基于磷酸基的CTH剂量。然而,有希望的结果需要进一步的研究。
{"title":"Pharmacokinetic-Based Chemotherapy Dosing in Advanced Head and Neck Cancer: A Mini Review","authors":"Abdelhamid M. Fouad, A. Gabal, Mariam Elhaddad","doi":"10.21608/RESONCOL.2019.10154.1074","DOIUrl":"https://doi.org/10.21608/RESONCOL.2019.10154.1074","url":null,"abstract":"Despite the continuous evolution in different treatment modalities for head and neck cancer (HNC), severe side effects of medications remain a challenge. Chemotherapy (CTH)-induced toxicities may lead to alterations in the treatment plan in the form of dose reduction, treatment delay or even discontinuation of treatment. Many efforts were done to overcome the impact of CTH-induced toxicity on HNC treatment. One of the explored strategies is the pharmacokinetic (PK)-based dosing of CTH. A literature search for trials investigating PK-based CTH dosing in HNC from 1988 to 2018 was performed. Few clinical studies including one randomized clinical trial were identified. The limited evidence obtained from these studies shows that PK-based CTH dosing in HNC results in significantly less toxicities with no detrimental impact on treatment outcome. The current evidence is not enough to recommend the routine use of PK-based CTH dosing in HNC. However, the promising results call for future studies.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42932635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Retrospective Analysis of Prognostic Factors in Adult Glioblastoma Multiforme: A Single Institution Experience 成人多型胶质母细胞瘤预后因素的回顾性分析:单一机构经验
Pub Date : 2019-02-02 DOI: 10.21608/RESONCOL.2019.6360.1071
M. Moumen, L. E. E. Arab, N. Mosalam, A. Gaballah
Background: Primary brain tumors represent 2% of cancers in adults. Glioblastoma Multiforme (GBM) is the most frequent among these tumors. Different prognostic factors have been identified including age, performance status, extent of surgery and genetic factors. Aim: To analyze treatment outcome and prognostic factors in adult patients with GBM treated at a single institution. Methods: We retrospectively collected the data of patients treated for GBM form January 2012 till December 2016. During this 5-years period, 111 patients were identified and the data of 93(84%) of them was complete and included in the analysis. Results: Males represented 67% of patients, their median age was 52 years and the Eastern Cooperative Oncology Group (ECOG) performance status was 1, 2 and 3 in 48%, 40% and 12% respectively. Only 4.3% of patients underwent complete surgical resection, 38% underwent partial resection and 58% underwent biopsy. Post-operative treatment was radiotherapy alone in 30% of patients and chemo-radiotherapy in 70%. The median progression-free survival (PFS) and overall survival (OS) were 8 months (95% Confidence Interval: 6.678-9.322) and 10 months (95% Confidence Interval: 7.522-12.487), respectively. Longer PFS was associated with age Conclusion: Glioblastoma Multiforme remains an aggressive disease with high mortality rate and poor outcome. Complete resection and adjuvant chemo-radiotherapy improve PFS and OS.
背景:原发性脑肿瘤占成人癌症的2%。多形性胶质母细胞瘤是这些肿瘤中最常见的。不同的预后因素已被确定,包括年龄、运动状态、手术程度和遗传因素。目的:分析在单一机构治疗的成年GBM患者的治疗结果和预后因素。方法:回顾性收集2012年1月至2016年12月收治的GBM患者资料。在这5年期间,共发现111例患者,其中93例(84%)的数据完整并纳入分析。结果:男性占67%,中位年龄52岁,东部肿瘤合作组(ECOG)成绩为1、2、3的分别占48%、40%、12%。只有4.3%的患者进行了完全手术切除,38%的患者进行了部分切除,58%的患者进行了活检。术后单纯放疗占30%,化疗加放疗占70%。中位无进展生存期(PFS)和总生存期(OS)分别为8个月(95%可信区间:6.678-9.322)和10个月(95%可信区间:7.522-12.487)。结论:多形性胶质母细胞瘤是一种侵袭性疾病,死亡率高,预后差。完全切除和辅助放化疗可改善PFS和OS。
{"title":"Retrospective Analysis of Prognostic Factors in Adult Glioblastoma Multiforme: A Single Institution Experience","authors":"M. Moumen, L. E. E. Arab, N. Mosalam, A. Gaballah","doi":"10.21608/RESONCOL.2019.6360.1071","DOIUrl":"https://doi.org/10.21608/RESONCOL.2019.6360.1071","url":null,"abstract":"Background: Primary brain tumors represent 2% of cancers in adults. Glioblastoma Multiforme (GBM) is the most frequent among these tumors. Different prognostic factors have been identified including age, performance status, extent of surgery and genetic factors. Aim: To analyze treatment outcome and prognostic factors in adult patients with GBM treated at a single institution. Methods: We retrospectively collected the data of patients treated for GBM form January 2012 till December 2016. During this 5-years period, 111 patients were identified and the data of 93(84%) of them was complete and included in the analysis. Results: Males represented 67% of patients, their median age was 52 years and the Eastern Cooperative Oncology Group (ECOG) performance status was 1, 2 and 3 in 48%, 40% and 12% respectively. Only 4.3% of patients underwent complete surgical resection, 38% underwent partial resection and 58% underwent biopsy. Post-operative treatment was radiotherapy alone in 30% of patients and chemo-radiotherapy in 70%. The median progression-free survival (PFS) and overall survival (OS) were 8 months (95% Confidence Interval: 6.678-9.322) and 10 months (95% Confidence Interval: 7.522-12.487), respectively. Longer PFS was associated with age Conclusion: Glioblastoma Multiforme remains an aggressive disease with high mortality rate and poor outcome. Complete resection and adjuvant chemo-radiotherapy improve PFS and OS.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41925498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Low-dose versus Standard-Dose Leucovorin in the Treatment of Colon Cancer: Mansoura University Clinical Experience in Facing the Problem of Leucovorin Shortage 低剂量与标准剂量Leucovorin治疗结肠癌癌症:Mansoura大学应对Leucovirin短缺问题的临床经验
Pub Date : 2019-01-02 DOI: 10.21608/RESONCOL.2018.6256.1069
H. Elkalla, M. Zahi, Osama Eldamshety
Background: Drug shortages have become a health care problem worldwide. One of the important drugs that are affected by shortage is leucovorin. It is used with 5-fluorouracil in many protocols for gastro-intestinal tumors and its shortage would have a negative impact on the treatment outcome. Aim: To compare the effect of low-dose leucovorin versus the standard-dose in the treatment of stage II and III colon cancer. Methods: The study included 100 patients with stage II or III adenocarcinoma of the colon who presented to the Clinical Oncology Department at Mansoura University Hospital from January 2011 till December 2012 after curative resection and were scheduled to receive adjuvant FOLFOX6 regimen. Patients were randomly allocated to receive standard-dose leucovorin (200 mg/m2, group 1) or low-dose leucovorin (125 mg/m2, group 2), both administered on days 1 and 2 over 2 hours infusion before 5-fluoruracil. The end points were toxicity, disease free survival (DFS) and overall survival (OS). Results: The two study groups were matched regarding age, sex, and tumor stage. The mean DFS was 48.36 months for group 1 and 49.12 for group 2 with no significant difference (p=0.866). The mean OS was 65.07 months for group 1 and 62.45 for group 2 with no significant difference (p=0.544). Similarly, there was no significant difference between the two groups regarding hematosuppression, diarrhea, mucositis, neurotoxicity and the need for hospitalization. Conclusion: Both protocols were well tolerated by all patients with no significant difference in the treatment outcome. The use of low-dose leucovorin protocol can help in solving the leucovorin shortage problem.
背景:药物短缺已成为一个全球性的卫生保健问题。受短缺影响的重要药物之一是亚叶酸素。它与5-氟尿嘧啶在许多胃肠道肿瘤治疗方案中一起使用,缺乏它会对治疗结果产生负面影响。目的:比较低剂量亚叶酸素与标准剂量治疗II期和III期结肠癌的疗效。方法:研究纳入2011年1月至2012年12月在曼苏拉大学医院临床肿瘤科就诊的结肠II期或III期腺癌患者100例,这些患者在治愈性切除后,计划接受FOLFOX6辅助治疗方案。患者随机分配接受标准剂量亚叶酸钙(200 mg/m2,组1)或低剂量亚叶酸钙(125 mg/m2,组2),均在5-氟尿嘧啶前第1天和第2天输注2小时。终点为毒性、无病生存期(DFS)和总生存期(OS)。结果:两个研究组在年龄、性别和肿瘤分期方面是匹配的。1组患者的平均生存期为48.36个月,2组患者的平均生存期为49.12个月,差异无统计学意义(p=0.866)。组1平均OS为65.07个月,组2平均OS为62.45个月,差异无统计学意义(p=0.544)。同样,两组在血液抑制、腹泻、粘膜炎、神经毒性和住院需求方面也没有显著差异。结论:两种治疗方案均具有良好的耐受性,治疗效果无显著差异。低剂量亚叶酸素方案的使用有助于解决亚叶酸素短缺问题。
{"title":"Low-dose versus Standard-Dose Leucovorin in the Treatment of Colon Cancer: Mansoura University Clinical Experience in Facing the Problem of Leucovorin Shortage","authors":"H. Elkalla, M. Zahi, Osama Eldamshety","doi":"10.21608/RESONCOL.2018.6256.1069","DOIUrl":"https://doi.org/10.21608/RESONCOL.2018.6256.1069","url":null,"abstract":"Background: Drug shortages have become a health care problem worldwide. One of the important drugs that are affected by shortage is leucovorin. It is used with 5-fluorouracil in many protocols for gastro-intestinal tumors and its shortage would have a negative impact on the treatment outcome. Aim: To compare the effect of low-dose leucovorin versus the standard-dose in the treatment of stage II and III colon cancer. Methods: The study included 100 patients with stage II or III adenocarcinoma of the colon who presented to the Clinical Oncology Department at Mansoura University Hospital from January 2011 till December 2012 after curative resection and were scheduled to receive adjuvant FOLFOX6 regimen. Patients were randomly allocated to receive standard-dose leucovorin (200 mg/m2, group 1) or low-dose leucovorin (125 mg/m2, group 2), both administered on days 1 and 2 over 2 hours infusion before 5-fluoruracil. The end points were toxicity, disease free survival (DFS) and overall survival (OS). Results: The two study groups were matched regarding age, sex, and tumor stage. The mean DFS was 48.36 months for group 1 and 49.12 for group 2 with no significant difference (p=0.866). The mean OS was 65.07 months for group 1 and 62.45 for group 2 with no significant difference (p=0.544). Similarly, there was no significant difference between the two groups regarding hematosuppression, diarrhea, mucositis, neurotoxicity and the need for hospitalization. Conclusion: Both protocols were well tolerated by all patients with no significant difference in the treatment outcome. The use of low-dose leucovorin protocol can help in solving the leucovorin shortage problem.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44894096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Cross-Sectional Study of Burnout among a Group of Egyptian Oncologists at Ain Shams University 艾因沙姆斯大学一组埃及肿瘤学家倦怠的横断面研究
Pub Date : 2018-11-19 DOI: 10.21608/RESONCOL.2018.3478.1056
R. Ghali, D. Boulos, M. Alorabi
Background: Oncologists are at risk of developing burn out syndrome due to many stressors they may face. Aim: To determine the level of burnout in a cohort of clinical oncologists working in an Egyptian university hospital. Methods: Fifty-two clinical oncologists were invited to participate in the study. Burnout was assessed using the Arabic version of Maslach Burnout Inventory Human Services Survey (MBI-HSS).Results: The response rate was 90% (47/52).  The majority (70%) of responders were young oncologists and 62% had >10 years experience in the oncology field. Females represented 52% of them and 62% were married. The MBI-HSS scores indicated that 72% of participants had burnout on the emotional exhaustion (EE) scale, 49% on the depersonalization (DP) scale and 38% on the personal accomplishment (PA) scale. A significantly lower PA score was associated with female gender, being single, viewing vacation time as insufficient, and an experience duration <10 years in oncology (p = 0.01, 0.01, 0.03, and 0.02; respectively). The preference not to choose again oncology as a career was also associated with significantly lower PA score and higher EE score (p=0.02 and 0.001; respectively). Conclusion: The surveyed oncologists experienced high burnout. Larger studies are needed in order to assess the burden of the problem and to develop evidence-based interventions to reduce it.
背景:由于肿瘤学家可能面临的许多压力源,他们有发展倦怠综合征的风险。目的:了解在埃及某大学医院工作的临床肿瘤学家的职业倦怠水平。方法:邀请52名临床肿瘤学家参与研究。使用阿拉伯语版本的Maslach职业倦怠量表人力服务调查(MBI-HSS)来评估职业倦怠。结果:有效率为90%(47/52)。大多数应答者(70%)是年轻的肿瘤学家,62%在肿瘤学领域有10年的经验。其中女性占52%,62%已婚。MBI-HSS得分显示,情绪耗竭(EE)量表、人格解体(DP)量表和个人成就(PA)量表分别有72%、49%和38%的被试存在倦怠。PA评分较低与女性、单身、认为休假时间不足和肿瘤工作经验<10年相关(p = 0.01、0.01、0.03和0.02;分别)。不再选择肿瘤学作为职业的倾向也与较低的PA评分和较高的EE评分相关(p=0.02和0.001;分别)。结论:受访肿瘤医师存在较高的职业倦怠。需要进行更大规模的研究,以评估这一问题的负担,并制定以证据为基础的干预措施来减轻这一负担。
{"title":"Cross-Sectional Study of Burnout among a Group of Egyptian Oncologists at Ain Shams University","authors":"R. Ghali, D. Boulos, M. Alorabi","doi":"10.21608/RESONCOL.2018.3478.1056","DOIUrl":"https://doi.org/10.21608/RESONCOL.2018.3478.1056","url":null,"abstract":"Background: Oncologists are at risk of developing burn out syndrome due to many stressors they may face. Aim: To determine the level of burnout in a cohort of clinical oncologists working in an Egyptian university hospital. Methods: Fifty-two clinical oncologists were invited to participate in the study. Burnout was assessed using the Arabic version of Maslach Burnout Inventory Human Services Survey (MBI-HSS).Results: The response rate was 90% (47/52).  The majority (70%) of responders were young oncologists and 62% had >10 years experience in the oncology field. Females represented 52% of them and 62% were married. The MBI-HSS scores indicated that 72% of participants had burnout on the emotional exhaustion (EE) scale, 49% on the depersonalization (DP) scale and 38% on the personal accomplishment (PA) scale. A significantly lower PA score was associated with female gender, being single, viewing vacation time as insufficient, and an experience duration <10 years in oncology (p = 0.01, 0.01, 0.03, and 0.02; respectively). The preference not to choose again oncology as a career was also associated with significantly lower PA score and higher EE score (p=0.02 and 0.001; respectively). Conclusion: The surveyed oncologists experienced high burnout. Larger studies are needed in order to assess the burden of the problem and to develop evidence-based interventions to reduce it.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47338314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Corrigendum: Abd El Bary et al. Cost Effectiveness Analysis of Letrozole Compared with Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women with Endocrine Responsive Breast Cancer. Kasr El-Aini J Clin Oncol Nucl Med. 2009; 5(3-4): 11-17. 更正:Abd-El-Bary等人。来曲唑与三苯氧胺作为内分泌反应性乳腺癌绝经后妇女的初始辅助治疗的成本效益分析。Kasr El Aini临床肿瘤学杂志,2009;5(3-4):11-17。
Pub Date : 2018-11-08 DOI: 10.21608/RESONCOL.2018.6131.1067
N. Bary, M. Maher, Mohamed M Elsherbini, M. Abdeen, T. Hashem
This corrigendum corrects the author list and affiliations of the article: Abd El Bary et al. Cost Effectiveness Analysis of Letrozole Compared with Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women with Endocrine Responsive Breast Cancer. Kasr El-Aini J Clin Oncol Nucl Med. 2009; 5(3-4): 11-17.In response to a request supported by documents from the corresponding author, the name Dr. Mohamed Elsherbini was added to the list of authors and the affiliation of Dr. Mohamed Abdeen was mentioned.The corrected version of this article replaces the primarily published one.
本更正更正了这篇文章的作者名单和隶属关系:Abd El Bary等人。来曲唑与三苯氧胺作为内分泌反应性癌症绝经后妇女初始辅助治疗的成本效益分析。Kasr El Aini临床肿瘤学杂志,2009;5(3-4):11-17根据通讯作者的文件支持的请求,Mohamed Elsherbini博士被添加到作者名单中,并提到Mohamed Abdeen博士的隶属关系。这篇文章的更正版本取代了最初发表的版本。
{"title":"Corrigendum: Abd El Bary et al. Cost Effectiveness Analysis of Letrozole Compared with Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women with Endocrine Responsive Breast Cancer. Kasr El-Aini J Clin Oncol Nucl Med. 2009; 5(3-4): 11-17.","authors":"N. Bary, M. Maher, Mohamed M Elsherbini, M. Abdeen, T. Hashem","doi":"10.21608/RESONCOL.2018.6131.1067","DOIUrl":"https://doi.org/10.21608/RESONCOL.2018.6131.1067","url":null,"abstract":"This corrigendum corrects the author list and affiliations of the article: Abd El Bary et al. Cost Effectiveness Analysis of Letrozole Compared with Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women with Endocrine Responsive Breast Cancer. Kasr El-Aini J Clin Oncol Nucl Med. 2009; 5(3-4): 11-17.In response to a request supported by documents from the corresponding author, the name Dr. Mohamed Elsherbini was added to the list of authors and the affiliation of Dr. Mohamed Abdeen was mentioned.The corrected version of this article replaces the primarily published one.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":"45 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41283553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Research in Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1